Cardiac arrhythmias secondary to hormone therapy in trans women

References

• Bauer G Transgender people in Ontario, Canada: statistics from the Trans PULSE project to inform human rights policy transgender people in Ontario, Canada Statistics from the Trans PULSE Project to Inform Human Rights Policy. 2015.
   Google Scholar
• Streed CG Jr, Harfouch O, Marvel F, et al. Cardiovascular disease among transgender adults receiving hormone therapy. Ann Intern Med. 2017;167:256–267.
   PubMed Web of Science ®Google Scholar
• Deutsch M Guidelines for primary and gender-affirming care of transgender and gender nonbinary people (2nd ed). Center of Excellence For Transgender Health [internet]. 2016 Available from: http://transhealth.ucsf.edu/guidelines (cited 2018 Nov 26
   Google Scholar
• Nokoff NJ, Scarbro S, Juarez-Colunga E, et al. Health and cardiometabolic disease in transgender adults in the United States: behavioral risk factor surveillance system 2015. J Endocr Soc. 2018;2:349–360.
   Google Scholar
• Bourns A Guidelines and Protocols For Hormone Therapy and Primary Health Care for Trans Clients. Sherbourne Health Centre. Available from: http://sherbourne.on.ca/wp-content/uploads/2014/02/Guidelines-and-Protocols-for-Comprehensive-Primary-Care-for-Trans-Clients-2015.pdf (cited 2018 Nov 16
   Google Scholar
• Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Clinical endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline. Endocr Pract. 2017;102:3869–3903.
   Google Scholar
• Gooren LJ, Wierckx K, Giltay EJ. Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. Eur J Endocrinol. 2014;170:809–819.
   PubMed Web of Science ®Google Scholar
• Bots SH, Peters SAE, Woodward M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. BMJ Glob Heal. 2017;2:2.
   Web of Science ®Google Scholar
• World Health Organization. WHO mortality database: World Health Organization 2015. http://www.who.int/healthinfo/statistics/mortality_rawdata/en/(Accessed 2019 Jan 24
   Google Scholar
• Asscheman H, Giltay EJ, Megens JA, et al. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011;164:635–642.
   PubMed Web of Science ®Google Scholar
• Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case- control study. Eur J Endocrinol. 2013;169:471–478.
   PubMed Web of Science ®Google Scholar
• Tadros R, Ton AT, Fiset C, et al. Sex differences in cardiac electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and mechanisms. Can J Cardiol. 2014;30:783–792.
   PubMed Web of Science ®Google Scholar
• Kurokawa J, Kodama M, Clancy CE, et al. Sex hormonal regulation of cardiac ion channels in drug-induced QT syndromes. Pharmacol Ther. 2016;168:23–28.
   PubMed Web of Science ®Google Scholar
• Odening KE, Koren G. How do sex hormones modify arrhythmogenesis in long QT syndrome? Sex hormome effects on arrhythmogenic substrate and triggered activity. Heart Rhythm. 2014;11:2107–2115.
   PubMed Web of Science ®Google Scholar
• Gillis AM. Atrial Fibrillation and. Ventricular arrhythmias: sex differences in electrophysiology, epidemiology, clinical presentation, and clinical outcomes. Circulation. 2017;134:593–608.
   Google Scholar
• Gaborit N, Varro A, Le Bouter S, et al. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. J Mol Cell Cardiol. 2010;49:639–646.
   PubMed Web of Science ®Google Scholar
• Tsai WC, Lu YY, Chen YC, et al. Ablation of androgen receptor gene triggers right venticular outflow tract ventricular tachycardia. Int J Cardiol. 2015;189:172–181.
   PubMed Web of Science ®Google Scholar
• Barber M, Nguyen LS, Wassermann J, et al. Cardiac arrhythmia considerations of hormone cancer therapies. Cardiovasc Res. 2019;115:878–894.
   PubMed Web of Science ®Google Scholar
• De Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93.
   PubMed Web of Science ®Google Scholar
• Salem JE, Alexandre J, Bachelot A, et al. Influence of steroid hormones on ventricular repolarization. Pharmacol Ther. 2016;167:38–47.
   PubMed Web of Science ®Google Scholar
• Scragg JL, Jones RD, Channer KS, et al. Testosterone is a potent inhibitor of L-type Ca 2+ channels. Biochem Biophys Res Commun. 2004;318:503–506.
   PubMed Web of Science ®Google Scholar
• Jones RD, Pugh PJ, Jones TH, et al. The vasodilatory action of testosterone : a potassium-channel opening or a calcium antagonistic action?. Br J Pharmacol. 2003;138:733–44.
   Google Scholar
• Tsai WC, Yang LY, Chen YC, et al. Ablation of the androgen receptor gene modulates atrial electrophysiology and arrhythmogenesis with calcium protein dysregulation. Endocrinology. 2018;154:2833–2842.
   Google Scholar
• Ohkusa T, Ueyama T, Yamada J, et al. Alterations in cardiac sarcoplasmic reticulum Ca2+ regulatory proteins in the atrial tissue of patients with chronic atrial fibrillation. J Am Coll Cardiol. 1999;34:255–263.
   PubMed Web of Science ®Google Scholar
• Brundel BJ, Van Gelder IC, Henning RH, et al. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasular Res. 1999;42:443–454.
   PubMed Web of Science ®Google Scholar
• Lai LP, Su MJ, Lin JL, et al. Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca (2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. J Am Coll Cardiol. 1999;33:1231–1237.
   PubMed Web of Science ®Google Scholar
• Tsuneda T, Yamashita T, Kato T, et al. Deficiency of testosterone associates with the substrate of atrial fibrillaiton in the rat model. J Cardiovasc Electrophysiol. 2009;20:1055–1060.
   PubMed Web of Science ®Google Scholar
• Masuda K, Takanari H, Morishima M, et al. Testosterone‑ mediated upregulation of delayed rectifier potassium channel in cardiomyocytes causes abbreviation of QT intervals in rats. J Physiol Sci. 2018;68(6):759–767.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang H, Wang Y, et al. Increment of late sodium currents in the left atrial myocytes and its potential contribution to increased susceptibility of atrial fibrillation in castrated male mice. Heart Rhythm. 2017;14(7):1073–1080.
   PubMed Web of Science ®Google Scholar
• Magnani JW, Moser CB, Murabito JM, et al. Association of sex hormones, aging, and atrial fibrillation in men: the framingham heart study. Circ Arrhythm Electrophysiol. 2014;7:307–312.
   PubMed Web of Science ®Google Scholar
• Rosenberg MA, Shores MM, Matsumoto AM, et al. Serum androgens and risk of atrial fibrillation in older men: the cardiovascular health study. Clin Cardiol. 2018;41:830–836.
   PubMed Web of Science ®Google Scholar
• Lai J, Zhou D, Xia S, et al. reduced testosterone levels in males with lone atrial fibrillation. Clin Cardiol. 2009;32:43–46.
   PubMed Web of Science ®Google Scholar
• Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J Am Heart Assoc. 2017;6:1-8.
   Web of Science ®Google Scholar
• Salem JE, Waintraub X, Courtillot C, et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation. 2018;138:110–113.
   PubMed Web of Science ®Google Scholar
• Bosco C, Bosnyak Z, Malmberg A, et al. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer : a meta-analysis. Eur Urol. 2015;68(3):386–396.
   PubMed Web of Science ®Google Scholar
• Siu CW, Huang H, Tse HF. Androgen deprivation therapy and adverse cardiovascular events in men with prostate cancer. J Am Coll Cardiol. 2012;59:E1739.
   Web of Science ®Google Scholar
• Tanaka Y, Tada H, Ito S, et al. Gender and age differences in candidates for radiofrequency catheter ablation of idiopathic ventricular arrhythmias. Circ J. 2011;75:1585–1591.
   PubMed Web of Science ®Google Scholar
• Hu X, Jiang H, Xu C, et al. Relationship between sex hormones and idiopathic outflow tract ventricular arrhythmias in adult male patients. Transl Res. 2009;154:265–268.
   PubMed Web of Science ®Google Scholar
• Dogan M, Yiginer O, Uz O, et al. The Effects of Female Sex Hormones on Ventricular Premature Beats and Repolarization Parameters in Physiological Menstrual Cycle. Pacing Clin Electrophysiol. 2016;39:418–426.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Katou S, Ichinose M, et al. Characteristics of new-onset ventricular arrhythmias in pregnancy. J Electrocardiol. 2004;37:47–53.
   PubMed Web of Science ®Google Scholar
• Soma-Pillay P, Nelson-Piercy C, Tolppanen H, et al. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27:89–94.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–737.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang J, Xu C, et al. Effect of oestrogen replacement therapy on idiopathic outflow tract ventricular arrhythmias in postmenopausal women. A Arch Cardiovasc Dis. 2011;104:84–88.
   PubMed Web of Science ®Google Scholar
• Wong JA, Rexrode K, Sandhu RK, et al. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart. 2018;103:1954–1961.
   Web of Science ®Google Scholar
• Perez MV, Wang PJ, Larson JC, et al. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the women‘s health initiative randomized controlled trials. Circ Arrhythm Electrophysiol. 2012;5:1108–1117.
   PubMed Web of Science ®Google Scholar
• Tsai W, Haung YB, Kuo HF, et al. Hormone replacement therapy and risk of atrial fibrillation in Taiwanese menopause women: A nationwide cohort study. Sci Rep. 2016;6:1-9.
   Web of Science ®Google Scholar
• Philip KJ, Hussain M, Byrne NF, et al. Greater antiarrhythmic activity of acute 17beta-estradiol in female than male anaesthetized rats: correlation with Ca2+ channel blockade. Br J Pharmacol. 2006;149:233–242.
   PubMed Web of Science ®Google Scholar
• Gooren L, Lips P. Conjectures concerning cross-sex hormone treatment of aging transsexual persons. J Sex Med. 2014;11:2012–2019.
   PubMed Web of Science ®Google Scholar
• Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol. 2018;19:67–71.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Yin H, Benayoun S, et al. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol. 2011;60:1244–1250.
   PubMed Web of Science ®Google Scholar